Drug Profile

GMA 304

Alternative Names: GMA-304

Latest Information Update: 28 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gmax Biopharm
Class Antihypertensives; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Atrial natriuretic factor receptor A agonists; Endothelin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Dec 2024 No recent reports of development identified for research development in Pulmonary-arterial-hypertension in China (Parenteral)
03 Nov 2020 GMA 304 is available for licensing as of 03 Nov 2020. http://www.gmaxbiopharm.com/job.html
03 Nov 2020 Early research in Pulmonary arterial hypertension in China (Parenteral) (Gmax Biopharm pipeline, November 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com